Research

Zacks Small Cap Analysis – CRVO: $150 Million Financing Strengthens Steadiness Sheet; Topline Knowledge for Part 2b Trial in 4Q24… – Model Slux

by
Zacks Small Cap Analysis – CRVO: 0 Million Financing Strengthens Steadiness Sheet; Topline Knowledge for Part 2b Trial in 4Q24… – Model Slux

By David Bautz, PhD NASDAQ:CRVO READ THE FULL CRVO RESEARCH REPORT Enterprise Replace Biomarker Knowledge Introduced at AD/PD 2024 On March 5, 2024, CervoMed Inc. (NASDAQ:CRVO) introduced the presentation of biomarker knowledge from the AscenD-LB Part 2a trial of neflamapimod in sufferers with dementia with Lewy our bodies (DLB) was featured in a poster presentation … Read more

CfP Oxford Early Careers Workshop; Chatham Home Surviving in Battle Occasion; CfP Western Sahara Analysis Group; Solange fiftieth Anniversary Convention – EJIL: Discuss! – Model Slux

by
CfP Oxford Early Careers Workshop; Chatham Home Surviving in Battle Occasion; CfP Western Sahara Analysis Group; Solange fiftieth Anniversary Convention – EJIL: Discuss! – Model Slux

1. Name for Papers: Oxford Workshop in Honour of Decide Theodor Meron  . The Oxford College College of Legislation, All Souls School, and Trinity School will host a workshop on 21 June 2024 in honour of Decide Theodor Meron, Visiting Professor of Worldwide Legislation on the College of Oxford and Honorary Fellow of Trinity School, … Read more

Zacks Small Cap Analysis – CTSO: CytoSorbents Expects Important Gross Margin Growth in 2024. – Model Slux

by

By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT For the total 12 months 2023, complete revenues elevated roughly 5.0% to $36.3 million. Complete product gross sales had been $31.1 million, a rise of 6.0% from 2022. 2022 gross sales benefitted from $0.7 million in different non-CytoSorb gross sales and $0.3 million in … Read more

Zacks Small Cap Analysis – AMS: Income Momentum, Footprint Enlargement, Prices Abating All Bode Effectively – Model Slux

by
Zacks Small Cap Analysis – AMS: Income Momentum, Footprint Enlargement, Prices Abating All Bode Effectively – Model Slux

By M. Marin NYSE:AMS READ THE FULL AMS RESEARCH REPORT Momentum accelerating, with Rhode Island most cancers facilities, plus new Linear Accelerator in Mexico representing new income sources… Based in 1983, American Shared Hospital Providers (NYSE:AMS), which supplies stereotactic radiosurgery gear and superior radiation remedy remedy methods to deal with most cancers sufferers, reported 2023 … Read more

Zacks Small Cap Analysis – HTCR: HeartCore Proclaims Sale of $9.0 Million in Go IPO Shopper Warrants. – Model Slux

by

By Thomas Kerr, CFA NASDAQ:HTCR READ THE FULL HTCR RESEARCH REPORT On April 1, 2024, HeartCore Enterprises (NASDAQ:HTCR) introduced it had licensed a dividend fee within the quantity of $0.02 per share which can whole $417,283 to be paid by the corporate. After evaluating the Firm’s steadiness sheet and monetary profile, HeartCore and its Board … Read more

x